Whilst 68Ga-HBED-CC-PSMA PET-CT has been shown to impact management in between 39 and 62% of patients with BCR of prostate cancer after previous definitive treatment and in 21% of patients undergoing primary staging, no such data has yet been reported for 68Ga-THP-PSMA [17, 18]. Here, FOLH1 is linked to prostate carcinoma.